While preliminary safety data appears promising, more comprehensive human studies are needed to establish definitive dosing guidelines and safety parameters
- July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") , a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate
Elucidation of Primary (3N) and Vestigial (5) Heavy Metal-Binding Sites in Staphylococcus aureus pI258 CadC: Evolutionary Implications for Metal Ion Selectivity of ArsR/SmtB Metal Sensor Proteins
Cancer 121 , 157171 (2019)
Metabolic reprogramming and cancer progression
Testosterone Replacement therapy might seem like the ultimate anti-aging formula